Works matching DE "ERLOTINIB"

Results: 989

The War on Pancreatic Cancer: We Are Not There Yet.

Published in:

2014

By:

VARADHACHARY, GAURI R.;
WOLFF, ROBERT A.

Publication type:

Opinion

Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising Strategies.

Published in:

2014

By:

LOWERY, MAEVE A.;
O'REILLY, EILEEN M.

Publication type:

Opinion

Treatment of Metastatic Pancreatic Adenocarcinoma: A Review.

Published in:

Oncology (08909091), 2014, v. 28, n. 1, p. 70

By:

THOTA, RAMYA;
BERLIN, JORDAN D.;
PAUFF, JAMES M.

Publication type:

Article

Expanding Options for Pancreatic Cancer... So Where Do We Go From Here?

Published in:

Oncology (08909091), 2014, v. 28, n. 1, p. 5

By:

KO, ANDREW H.

Publication type:

Article

Tumor Inhibition Achieved by Targeting and Regulating Multiple Key Elements in EGFR Signaling Pathway Using a Self‐Assembled Nanoprodrug.

Published in:

Advanced Functional Materials, 2018, v. 28, n. 22, p. 1, doi. 10.1002/adfm.201800692

By:

Li, Bowen;
Xie, Xin;
Chen, Zelin;
Zhan, Chenyue;
Zeng, Fang;
Wu, Shuizhu

Publication type:

Article

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases.

Published in:

European Journal of Clinical Pharmacology, 2020, v. 76, n. 10, p. 1427, doi. 10.1007/s00228-020-02926-9

By:

Shriyan, Bharati;
Patil, Deepali;
Gurjar, Murari;
Nookala, Manjunath;
Patil, Anand;
Kannan, Sadhana;
Patil, Vijay;
Joshi, Amit;
Noronha, Vanita;
Prabhash, Kumar;
Gota, Vikram

Publication type:

Article

Epithelial growth factor receptor tyrosine kinase inhibitors alleviate house dust mite allergen Der p2‐induced IL‐6 and IL‐8.

Published in:

Environmental Toxicology, 2019, v. 34, n. 4, p. 476, doi. 10.1002/tox.22701

By:

Pan, Hui‐Hsien;
Hsiao, Yu‐Ping;
Chen, Ping‐Ju;
Kang, Yu‐Ting;
Chao, Yu‐Hua;
Sheu, Ji‐Nan;
Lue, Ko‐Huang;
Ko, Jiunn‐Liang

Publication type:

Article

Epidermal growth factor receptor (EGFR)-MAPK-nuclear factor(NF)-κB-IL8: A possible mechanism of particulate matter(PM) 2.5-induced lung toxicity.

Published in:

Environmental Toxicology, 2017, v. 32, n. 5, p. 1628, doi. 10.1002/tox.22390

By:

Jeong, Seung‐Chan;
Cho, Yoon;
Song, Mi‐Kyung;
Lee, Eunil;
Ryu, Jae‐Chun

Publication type:

Article

Physicochemical characterisation and cyclodextrin complexation of erlotinib.

Published in:

Supramolecular Chemistry, 2016, v. 28, n. 7/8, p. 656, doi. 10.1080/10610278.2015.1117083

By:

Tóth, Gergő;
Jánoska, Ádám;
Szabó, Zoltán-István;
Völgyi, Gergely;
Orgován, Gábor;
Szente, Lajos;
Noszál, Béla

Publication type:

Article

Squamous cell carcinoma of the lung.

Published in:

Oncolog-Hematolog, 2016, n. 36, p. 42

By:

Grigorescu, Alexandru

Publication type:

Article

非小细胞肺癌 EGFR-TKIs 治疗及PET分子成像的研究进展.

Published in:

Progress in Modern Biomedicine, 2020, v. 20, n. 4, p. 793, doi. 10.13241/j.cnki.pmb.2020.04.042

By:

褚晶晶;
杨丽丽;
刘姗姗;
孙夕林

Publication type:

Article

血清CEA、CA211 水平与晚期非小细胞肺癌靶向治疗患者疗效、预后的关系及其诊断价值分析

Published in:

Progress in Modern Biomedicine, 2019, v. 19, n. 18, p. 3527, doi. 10.13241/j.cnki.pmb.2019.18.028

By:

宁瑞玲;
于起涛;
曾爱屏;
王惠临;
赵文华;
蒋玮;
苏翠云

Publication type:

Article

丝氨酸生物合成途径介导肺腺癌细胞EGFR-TKIs 靶向治疗适应性耐药.

Published in:

Progress in Modern Biomedicine, 2019, v. 19, n. 17, p. 3218, doi. 10.13241/j.cnki.pmb.2019.17.004

By:

周烨;
顾玮铭;
梁倩;
罗鸣宇;
沈瑛

Publication type:

Article

Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.

Published in:

2021

By:

WANG, W.;
DONG, M.-L.;
ZHANG, W.;
LIU, T.

Publication type:

Correction Notice

Design, Synthesis, In Vitro Anticancer and ADMET Studies of Piperazine-Pyrazolo-Quinoxalin-2(1H)-one Conjugate as EGFR Targeting Agents.

Published in:

Russian Journal of General Chemistry, 2025, v. 95, n. 1, p. 184, doi. 10.1134/S1070363224610366

By:

Ferazoddin, M.;
Syeda, Arshiya Banu;
Syeda, Asra Banu;
Dasari, G.;
Bandari, S.

Publication type:

Article

Design and Synthesis of New Quinoxaline-thiazolidine-2,4-dione-isoxazole Conjugates as EGFR Targeting Agents.

Published in:

Russian Journal of General Chemistry, 2024, v. 94, n. 7, p. 1738, doi. 10.1134/S107036322407017X

By:

Srimath, Kurma;
Dasari, Gouthami;
Thirukovela, Narsimha Swamy;
Ravula, Sharada;
Bandari, Srinivas

Publication type:

Article

Synthesis, Anti-Breast Cancer, and EGFR Activity of Novel Pyrido[2,3-d]pyrimidine-piperazine-1,2,4-oxadiazoles.

Published in:

Russian Journal of General Chemistry, 2024, v. 94, n. 6, p. 1464, doi. 10.1134/S1070363224060239

By:

Jyothi, G.;
Palabindela, Rambabu;
Narsimha, Sirassu

Publication type:

Article

One-Pot Synthesis of 6-Amino-4-(furan/thiophen/pyrrol-2-yl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles, Evaluation of Anticancer Activity and Molecular Modelling Studies.

Published in:

Russian Journal of General Chemistry, 2023, v. 93, n. 1, p. 128, doi. 10.1134/S1070363223010188

By:

Kalpana, K.;
Rani, V. A.;
Ranga, A.;
Perumandla, R.;
Ramani, R.

Publication type:

Article

Synthesis and Anticancer Activity of Some New 4-Azaindoleisoxazoles.

Published in:

Russian Journal of General Chemistry, 2022, v. 92, n. 3, p. 470, doi. 10.1134/S107036322203015X

By:

kudapa, Venu;
B, Saritha;
Sailaja, B. B. V.

Publication type:

Article

Synthesis and Biological Activity of 3,9-Diazatetraasteranes as Novel EGFR Tyrosine Kinase Inhibitors.

Published in:

Russian Journal of General Chemistry, 2022, v. 92, n. 3, p. 446, doi. 10.1134/S1070363222030124

By:

Mao, Li;
Tian, Nana;
Wei, Chaochun;
Wang, Hongjun;
Yan, Hong

Publication type:

Article

The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.

Published in:

BioMed Research International, 2021, p. 1, doi. 10.1155/2021/6679082

By:

Yang, Jin-zhao;
Song, Yi;
Xiong, Jian-hua;
Lin, Yu-xian;
Wen, Congcong;
Li, Yu;
Zhou, Yunfang

Publication type:

Article

Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy.

Published in:

Brain Sciences (2076-3425), 2024, v. 14, n. 12, p. 1192, doi. 10.3390/brainsci14121192

By:

Olthoff, Karen;
Nigra, Ayelén D.;
Milla Sanabria, Laura N.

Publication type:

Article

Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes.

Published in:

Clinical & Translational Medicine, 2023, v. 13, n. 10, p. 1, doi. 10.1002/ctm2.1431

By:

Bai, Menglin;
Wu, Leilei;
Zhao, Mengyu;
Jin, Peng;
Liu, Jingru;
Wang, Weiqing;
Gao, Xuetian;
Wang, Yanan;
Chong, Wei;
Yu, Jinming;
Chen, Hao;
Meng, Xue

Publication type:

Article

APE1 shRNA‐loaded cancer stem cell‐derived extracellular vesicles reverse Erlotinib resistance in non‐small cell lung cancer via the IL‐6/STAT3 signalling.

Published in:

Clinical & Translational Medicine, 2022, v. 12, n. 5, p. 1, doi. 10.1002/ctm2.876

By:

Tang, Chun‐Han;
Qin, Ling;
Gao, Ying‐Chun;
Chen, Tai‐Yu;
Xu, Ke;
Liu, Tao;
Ren, Tao

Publication type:

Article

Matrix‐assisted laser desorption ionization ‐ mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non‐small‐cell lung cancer mouse xenograft model.

Published in:

Clinical & Translational Medicine, 2021, v. 11, n. 7, p. 1, doi. 10.1002/ctm2.481

By:

Kim, Tae Young;
Lee, Boram;
Kim, Yonghyo;
Sugihara, Yutaka;
Rezeli, Melinda;
Szasz, A. Marcell;
Dome, Balazs;
Marko‐Varga, Gyorgy;
Kwon, Ho Jeong

Publication type:

Article

Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study.

Published in:

Geriatrics & Gerontology International, 2021, v. 21, n. 10, p. 881, doi. 10.1111/ggi.14243

By:

Tsubata, Yukari;
Masuda, Takeshi;
Hamai, Kosuke;
Taniwaki, Masaya;
Tanino, Akari;
Hotta, Takamasa;
Hamaguchi, Megumi;
Hamaguchi, Shunichi;
Yamasaki, Masahiro;
Ishikawa, Nobuhisa;
Fujitaka, Kazunori;
Sutani, Akihisa;
Isobe, Takeshi

Publication type:

Article

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Published in:

Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 6, p. 661, doi. 10.1111/jcpt.12332

By:

Sohn, H. S.;
Kwon, J.‐W.;
Shin, S.;
Kim, H.‐S.;
Kim, H.

Publication type:

Article

A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.

Published in:

Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 4, p. 391, doi. 10.1111/jcpt.12273

By:

Lang, A.‐S.;
Mounier, M.;
Roques, M.;
Chretien, M. L.;
Boulin, M.

Publication type:

Article

Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.

Published in:

Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 2, p. 232, doi. 10.1111/jcpt.12232

By:

Emoto‐Yamamoto, Y.;
Iida, S.;
Kawanishi, T.;
Fukuoka, M.

Publication type:

Article

Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1335373

By:

Motta-Guerrero, Rodrigo;
Garrido-Lecca, Alejandro Leon;
Failoc-Rojas, Virgilio E.;
Calle-Villavicencio, Ana;
Villacorta-Carranza, Robert;
Huerta-Collado, Yesenia;
Torres-Mera, Alicia;
Valladares-Garrido, Mario J.;
Rivera-Francia, Víctor;
Carracedo, Carlos;
Raez, Luis

Publication type:

Article

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1283951

By:

Papoff, Giuliana;
Presutti, Dario;
Fustaino, Valentina;
Parente, Andrea;
Calandriello, Clelia;
Alemà, Stefano;
Scavizzi, Ferdinando;
Raspa, Marcello;
Merlino, Giuseppe;
Salerno, Massimiliano;
Bigioni, Mario;
Binaschi, Monica;
Ruberti, Giovina

Publication type:

Article

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2ndgeneration EGFR-tyrosine kinase inhibitors.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1249106

By:

Ping-Chih Hsu;
Chun-Yao Huang;
Yu-Ching Lin;
Suey-Haur Lee;
Li-Chung Chiu;
Chiao-En Wu;
Scott Chih-Hsi Kuo;
Jia-Shiuan Ju;
Allen Chung-Cheng Huang;
Ho-Wen Ko;
Chin-Chou Wang;
Cheng-Ta Yang

Publication type:

Article

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1238883

By:

Breitenecker, Kristina;
Hedrich, Viola;
Pupp, Franziska;
Chen, Doris;
Řezníčková, Eva;
Ortmayr, Gregor;
Huber, Heidemarie;
Weber, Gerhard;
Balcar, Lorenz;
Pinter, Matthias;
Mikulits, Wolfgang

Publication type:

Article

Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.

Published in:

EJNMMI Research, 2018, v. 8, n. 1, p. 1, doi. 10.1186/s13550-018-0434-0

By:

Amor, Dorra;
Goutal, Sébastien;
Marie, Solène;
Caillé, Fabien;
Bauer, Martin;
Langer, Oliver;
Auvity, Sylvain;
Tournier, Nicolas

Publication type:

Article

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Published in:

Lung Cancer: Targets & Therapy, 2017, v. 8, p. 109, doi. 10.2147/LCTT.S119644

By:

Santarpia, Mariacarmela;
Liguori, Alessia;
Karachaliou, Niki;
Gonzalez-Cao, Maria;
Daffinà, Maria Grazia;
D'Aveni, Alessandro;
Marabello, Grazia;
Altavilla, Giuseppe;
Rosell, Rafael

Publication type:

Article

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics.

Published in:

Lung Cancer: Targets & Therapy, 2014, v. 5, p. 73, doi. 10.2147/LCTT.S50671

By:

Karachaliou, Niki;
Rosell, Rafael

Publication type:

Article

EGFR-Blockade With Erlotinib Reduces EGF and TGF-β2 Expression and the Actin-Cytoskeleton Which Influences Different Aspects of Cellular Migration in Lens Epithelial cells.

Published in:

Current Eye Research, 2014, v. 39, n. 10, p. 1000, doi. 10.3109/02713683.2014.888453

By:

Wertheimer, C.;
Liegl, R.;
Kernt, M.;
Docheva, D.;
Kampik, A.;
Eibl-Lindner, K.H.

Publication type:

Article

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.

Published in:

International Journal of Cancer, 2022, v. 151, n. 9, p. 1565, doi. 10.1002/ijc.34144

By:

Jo, Jung Hyun;
Jung, Dawoon E.;
Lee, Hee Seung;
Park, Soo Been;
Chung, Moon Jae;
Park, Jeong Youp;
Bang, Seungmin;
Park, Seung Woo;
Cho, Sangsook;
Song, Si Young

Publication type:

Article

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).

Published in:

International Journal of Cancer, 2021, v. 148, n. 3, p. 682, doi. 10.1002/ijc.33225

By:

Assenat, Eric;
Mineur, Laurent;
Mollevi, Caroline;
Lopez‐Crapez, Evelyne;
Lombard‐Bohas, Catherine;
Samalin, Emmanuelle;
Portales, Fabienne;
Walter, Thomas;
Forges, Hélène;
Dupuy, Marie;
Boissière‐Michot, Florence;
Ho‐Pun‐Cheung, Alexandre;
Ychou, Marc;
Mazard, Thibaut

Publication type:

Article

Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Published in:

International Journal of Cancer, 2020, v. 147, n. 2, p. 472, doi. 10.1002/ijc.32598

By:

Gurtner, Kristin;
Kryzmien, Zofia;
Koi, Lydia;
Wang, Meng;
Benes, Cyril H.;
Hering, Sandra;
Willers, Henning;
Baumann, Michael;
Krause, Mechthild

Publication type:

Article

Osimertinib confers potent binding affinity to EGFR kinase domain duplication.

Published in:

International Journal of Cancer, 2019, v. 145, n. 10, p. 2884, doi. 10.1002/ijc.32617

By:

Jin, Rui;
Li, Jie;
Jin, Zhou;
Lu, Yuefei;
Shao, Yang W.;
Li, Wen;
Zhao, Guofang;
Xia, Yang

Publication type:

Article

From "Glivec®" to "Prevnar 13®": How strong is the Indian drug patenting system?

Published in:

2018

By:

Raj, Gerard Marshall

Publication type:

Letter to the Editor

Cutaneous Side Effects During Therapy With Erlotinib - Case Report.

Published in:

2021

By:

Jovičić, Sanja;
Gajanin, Vesna;
Umičević-Šipka, Sanja

Publication type:

Case Study

In-silico DESIGN SCREENING OF SOME PYRAZOLONE FUSED HETEROCYCLIC ANALOGUES AS HER2 INHIBITORS TARGETING BREAST CANCER.

Published in:

Rasayan Journal of Chemistry, 2022, v. 15, n. 1, p. 497, doi. 10.31788/RJC.2022.1516738

By:

Sumathy, A.;
Suresh, R.;
Gowrishankar, N. L.

Publication type:

Article

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) OF N-BENZOYL-N'-PHENYLTHIOUREA COMPOUND AND DERIVATIVES IN MCF-7 CANCER CELLS.

Published in:

Rasayan Journal of Chemistry, 2021, v. 14, n. 4, p. 2698, doi. 10.31788/RJC.2021.1446357

By:

Kesuma, D.;
Santosa, H.;
Nasyanka, A. L.;
Ruswanto

Publication type:

Article

DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR THE ESTIMATION OF ERLOTINIB IMPURITIES BY QbD APPROACH.

Published in:

Rasayan Journal of Chemistry, 2016, v. 9, n. 2, p. 180

By:

Kumar, P. A.;
Kumar, Y. R.;
Jayashree, A.

Publication type:

Article

Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study.

Published in:

Acta Oncologica, 2021, v. 60, n. 9, p. 1100, doi. 10.1080/0284186X.2021.1937309

By:

Alanen, Virve;
Iivanainen, Sanna;
Arffman, Martti;
Koivunen, Jussi P.

Publication type:

Article

NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.

Published in:

Genes, 2023, v. 14, n. 3, p. 607, doi. 10.3390/genes14030607

By:

Madajewski, Brian;
Boatman, Michael A.;
Martinez, Ivan;
Carter, Julia H.;
Bey, Erik A.

Publication type:

Article

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation.

Published in:

Acta Dermato-Venereologica, 2024, v. 104, p. 1, doi. 10.2340/actadv.v104.40975

By:

Yujing WANG;
Wenjie HUANG;
Haidong JIA;
Qinglian TANG;
Qingfei YIN;
Yuanyuan CHEN;
Wumei WANG;
Zhengyu CAO

Publication type:

Article

Comparative of in-vitro Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line.

Published in:

Iranian Journal of Pharmaceutical Research, 2019, v. 18, n. 3, p. 1168, doi. 10.22037/ijpr.2019.1100775

By:

Gaballu, Fereydoon Abedi;
Abbaspour-Ravasjani, Soheil;
Mansoori, Behzad;
Yekta, Reza;
Hamishehkar, Hamed;
Mohammadi, Ali;
Dehghan, Gholamreza;
Shokouhi, Behrooz;
Dehbokri, Shaho Ghahremani;
Baradaran, Behzad

Publication type:

Article